Skip to main content
main-content

07-11-2021 | ACR 2021 | Conference coverage | Video

Risankizumab for PsA: How will the KEEPsAKE 1 and 2 findings impact clinical practice?

Laura Coates comments on the results of the KEEPsAKE 1 and 2 studies, and explores where risankizumab may fit in the treatment landscape for psoriatic arthritis (5.10).

Read transcript

ACR Convergence 2021 highlights

3–9 November: Keep up with the latest news and interviews from the conference.

Image Credits